We have demonstrated that D-glucose kinetics detected by dynamic glucose-enhanced (DGE)-MRI can be used to assess D-glucose uptake and clearance alterations in Alzheimer’s disease (AD) mice at 3T. Interleukin (IL)-33 treatment has been shown to promote Aβ clearance. Here, we applied our established DGE-MRI to detect changes of brain clearance after IL-33 treatment in cerebrospinal fluid (CSF) and brain parenchyma in AD mice. A significant increased D-glucose clearance from CSF, but not brain parenchyma, was observed after treatment. DGE-MRI provides a non-invasive evaluation of IL-33 treatment in AD, and further affirm its potential to assess brain lymphatic system in AD.